News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Temozolomide Not Superior to Procarbazine-Based Combination Treatment in Patients With High-Grade Glioma: Presented at ESMO


Posted on: 09/28/2008

Temozolomide Not Superior to Procarbazine-Based Combination Treatment in Patients With High-Grade Glioma: Presented at ESMO

By Ed Susman

STOCKHOLM, Sweden -- September 18, 2008 -- Treating patients with temozolomide monotherapy is not more effective than the standard therapy of procarbazine, lomustine, and vincristine (PCV) in a clinical trial involving patients with high-grade gliomas, according to a study presented here at the 33rd European Society for Medical Oncology Congress (ESMO).

Patients in the study who were assigned to temozolomide achieved 7.2 months of progression-free survival compared with 6.7 months among patients assigned to the PCV regimen, a 9% decreased risk of disease progression.

Ming Lee, MD, University College Hospitals, London, United Kingdom, presented the study results during the late-breaker symposium on September 15.

Median time to progression was 4.7 months in the temozolomide patients and 3.6 months in the PCV patients, a nonsignificant difference (= .23) for the secondary endpoint outcome.

Dr. Lee and colleagues also subdivided the temozolomide patients into 2 groups: a 5-day treatment of 200 mg/m2 every 28 days or a 21-day treatment of 100 mg/m2 in a 28-day cycle. Patients were given a maximum of 9 cycles or until disease progression occurred.

After 12 weeks, 63.6% of patients receiving the 5-day treatment exhibited no signs of progression compared with 65.7% the patients on the 21-day treatment with temozolomide, again showing no significant difference (= .75). However, there was a difference in progression-free survival among the 5-day temozolomide patients and those getting the longer treatment.

Dr. Lee said patients on the shorter therapy had a 5-month progression-free survival compared with a median of 4.2 months for those patients on the prolonged treatment (= .02). There was also a strong trend (= .06) for a longer survival among patients who received the 5-day treatment (8.5 months) compared with 6.8 months for patients on the 21-day regimen.

"Temozolomide-5 was superior to temozolomide-21 schedule with respect to progression-free survival and overall survival," Dr. Lee said. "These results question the current basis of increasing temozolomide dose intensity by prolonging scheduling."

[Presentation title: A Randomised Trial of Procarbazine, CCNU and Vincristine (PCV) vs Temozolomide (5-Day or 21-Day Schedule) for Recurrent High Grade Glioma (MRC BR12, ISRCTN83176944). LBA5] 
 

Source: http://www.docguide.com/news/content.nsf/news/852571020057CCF6852574C8005AA163

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites